Managing Clinically Significant Drug Interactions in Patients with HIV and Comorbid Conditions

Activity Preview

The objective of this activity is to review common drug interactions associated with the use of anti-retroviral (ARV) agents for treatment of HIV and comorbid conditions, and to provide pharmacists with guidance for managing potential interactions. Many potential pharmacokinetic mechanisms, including reduced absorption and altered metabolism, can precipitate clinically significant drug interactions. An understanding of these mechanisms as well as familiarity with drug interaction resources and databases are necessary for appropriate medication management of patients with HIV.



Learning Objectives

After participating in this activity, the pharmacist will be able to:

  1. Examine common pharmacologic mechanisms of drug-drug interactions associated with antiretroviral agents (ARVs) used in the treatment of HIV.
  2. Evaluate the consequences of drug interactions associated with ARVs and determine the likelihood of clinically significant drug interactions.
  3. Formulate a list of drugs that have a high potential to interact with ARVs.
  4. Explain strategies that can be used to minimize the incidence of adverse drug interactions associated with ARVs. 

Activity type: Knowledge-based
Learning Level: 2


Accreditation Information

ACPE logo

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

To obtain 2.0 contact hours of continuing pharmacy education credit (0.2 CEUs) for completing "Managing Clinically Significant Drug Interactions in Patients with HIV and Comorbid Conditions," complete the CPE examination and evaluation questions. Credit will be awarded upon achieving a passing grade of 70% or better.  Please visit CPE Monitor for your statement of credit/transcript.

APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education examination. Please note that you will not be permitted to submit the examination a third time. Exam questions may not appear in the same order as printed.

The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the test. Individuals completing this activity by June 1, 2019 can receive credit.

Initial release date: June 1, 2016
Expiration date: June 1, 2019
ACPE Universal Activity Number: 0202-0000-16-124-H02-P


Advisory Board

Professor of Clinical Pharmacy and Family and Community Medicine
University of California Schools of Pharmacy and Medicine
San Francisco, California



Betty J. Dong, PharmD, FCCP, FASHP, FAPHA, AAHIVP, declares no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants, employment, gifts, stock holdings, and honoraria. APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, please see the APhA Accreditation Information section at



"Managing Clinically Significant Drug Interactions in Patients with HIV and Comorbid Conditions” is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.


Activity Fee

There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.

Credit Information

Activity Number Credit Amount Accreditation Period
ACPE# 0202-0000-16-124-H02-P 0.2 CEUs June 01, 2016 - June 01, 2019